Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.86 |
| ▸ | CNR1 | P21554 | 2/20 | 0.86 |
| ▸ | CNR2 | P34972 | 2/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.86 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | INHA | P05111 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | HTR2A | P28223 | 1/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.86 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.86 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.86 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.86 |
| ▸ | MAOB | P27338 | 6/20 | 0.63 |
| ▸ | APP | P05067 | 4/20 | 0.63 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.58 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cannabigerol SCHEMBL12954626 | 0.92 | PPARG (1.00) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| Cannabigerol SCHEMBL14764730 | 0.92 | PPARG (1.00) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| Cannabigerol SCHEMBL144819 | 0.92 | PPARG (1.00) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23523643 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23523554 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23522965 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23522969 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23523042 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23523493 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 | |
| SCHEMBL23523492 | 0.91 | PPARG (0.97) | PPARGCNR1CNR2TRPV1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239694-A1 | CANNABINOID CONJUGATE MOLECULES COMPRISING AN AVERMECTIN COMPONENT | DIVERSE BIOTECH, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230381205-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | INMED PHARMACEUTICALS INC. (CA) | 2023-11-30 | — | — | US | disclosed |
| EP-3368014-B1 | NOVEL CANNABINOID FORMULATIONS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023015253-A1 | CANNABINOID DERIVATIVES AND THEIR USE | DEMEETRA AGBIO, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2020263893-A1 | CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020263975-A1 | BETA-LACTAM-CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381205-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | CNR2, CNR1, GAP43 | PPARG 1354/4885CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.